PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Amphera and Alligator Bioscience reveal mitazalimab-MesoPher update

Therapy is being used during a pivotal phase 1 study into patients with pancreatic cancer.

Alligator Bioscience and Amphera have announced that the last patient in their REACTIVE-2 phase 1 research has been dosed. The research is evaluating mitazalimab when used in combination with MesoPher among patients with metastatic pancreatic cancer.

The single-location, open-label trial is assessing the efficacy and safety of Alligator’s lead candidate mitazalimab along with Amphera’s cancer vaccine MesoPher. It involves patients who have already undergone standard-of-care treatment with mFOLFIRINOX.

The REACTIVE-2 study is currently being performed at Erasmus Medical Center in Rotterdam, the Netherlands, while initial results are expected later this year.

Søren Bregenholt, chief executive officer at Alligator Bioscience, reflected: “Our CD40 agonist and Amphera’s cancer vaccine have both shown great promise in their own separate clinical studies emphasising the crucial role of dendritic cells and other myeloid cells in the immune response to pancreatic cancer.”

He added: “We have high hopes that a combination of mitazalimab and MesoPher can drive clinically meaningful anti-tumour immunity and potentially offer a new therapeutic option in this hard-to-treat patient population.”

Rob Meijer, chief executive officer at Amphera, concluded: “We are very pleased to have successfully reached this important milestone in the REACTIVE-2 trial. MesoPher is able to invigorate the immune system without toxicity to the patient. This makes MesoPher ideally suited in combination treatments for difficult-to-treat cancer indications.”

Meanwhile, Mitazalimab is also being researched when used in combination with mFOLFIRINOX during OPTIMIZE-1, a phase 2 trial in patients with metastatic pancreatic cancer who have yet to be treated. Earlier this year, Alligator revealed strong interim results from OPTIMIZE-1, which demonstrated an objective response rate of 52% among 23 patients.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026